




RealRate

PHARMACEUTICAL 2022

Sarepta Therapeutics Inc.
Rank 324 of 466



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Sarepta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 39% points. The greatest weakness of Sarepta Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 44%, being 34% points below the market average of 78%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 2,604,099 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 14,239 |
| Liabilities, Current | 452,733 |
| Liabilities, Non-Current | 626,756 |
| Other Assets | 338,480 |
| Other Compr. Net Income | -23 |
| Other Expenses | 107,587 |
| Other Liabilities | 1,140,476 |
| Other Net Income | 40,762 |
| Other Revenues | 701,887 |
| Property and Equipment | 191,156 |
| Research and Development | 771,182 |
| Selling, General and Administrative Expense | 282,660 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 3,147,974 |
| Liabilities | 2,219,965 |
| Expenses | 1,161,429 |
| Revenues | 701,887 |
| Stockholders Equity | 928,009 |
| Net Income | -418,780 |
| Comprehensive Net Income | -418,792 |
| Economic Capital Ratio | 44% |